Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden and efficacy of chemotherapy in lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jan 2023

Song Juan, Yan Yu, Chen Cuicui, Li Jiamin, Ding Ning, Xu Nuo, Bao Hairong, Zhang Xin, Hong Qunying, Zhou Jian, Shao Yang W, Song Yuanlin, Tong Lin, Hu Jie

Abstract excerpt

PURPOSE: TMB is one of the potent biomarkers of response to immune checkpoint blockade. The association between TMB and efficacy of chemotherapy in advanced lung cancer has not been comprehensively explored. METHODS: Ninety lung cancer patients receiving first-line chemotherapy with large panel next-generation sequencing data of pre-treatment tumor tissue were identified. The effect of TMB on PFS of chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 35995891
DOI: 10.1007/s12094-022-02924-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden and efficacy of chemotherapy in lung cancer.PMID 35995891Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

TMB in NSCLC: A Broken Dream?Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.Semantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.Semantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.